AI Article Synopsis
- Immune checkpoint inhibitors (ICIs) significantly improve survival rates for melanoma patients, but the impact of body mass index (BMI) and type 2 diabetes (T2DM) on these outcomes has been unclear.
- In a study of 2,078 melanoma patients, overweight individuals (BMI≥25 kg/m²) had better median overall survival (71.7 months) compared to non-overweight individuals (36.7 months), while those with T2DM experienced worse survival (28.5 months).
- The research shows that overweight patients maintained better survival outcomes even after accounting for T2DM, highlighting that being overweight could be advantageous in this context, whereas T2DM negatively affects survival in melanoma patients receiving ICIs.
Article Abstract
Background: Immune checkpoint inhibitors (ICIs) have improved survival outcomes in melanoma. Studies exploring the correlations between body mass index (BMI), type 2 diabetes (T2DM) and the outcomes of ICI treatment have yielded inconsistent results. In this study, we aim to investigate the effects of BMI and T2DM on survival outcomes of patients with melanoma receiving ICIs.
Methods: A retrospective multicenter cohort of patients with melanoma treated with ICIs was analyzed. Overall survival was evaluated with Kaplan-Meier survival analysis, univariate Cox and multivariate Cox proportional hazards model. Propensity-score matching (1:1) analysis between overweight and non-overweight groups was done and survival analyses and Cox analyses were performed again. Subgroup analyses and secondary analyses stratifying patients with different weights and T2DM statuses were also performed.
Results: A total of 2,078 patients were included, of whom 1,412 were overweight (BMI≥25 kg/m) and 666 were non-overweight (BMI<25 kg/m). Overweight patients had better overall survival compared with non-overweight (median 71.7 vs 36.7 months, p<0.001). Patients with T2DM had worse overall survival compared with patients without T2DM (median 28.5 vs 67.3 months, p<0.001). After propensity-score matching (666 overweight were matched to 666 non-overweight), overweight patients remained to have better overall survival compared with non-overweight (median 67.7 vs 36.7 months, p<0.001). Patients with T2DM had worse survival in univariate Cox (HR 1.71, (95% CI: 1.20 to 2.43)) and multivariate Cox (HR 1.58, (95% CI: 1.08 to 2.31)) analyses. Overweight patients without T2DM had the best survival outcomes compared with other weight and T2DM combinations.
Conclusion: In patients with melanoma treated with ICIs, being overweight had better survival outcomes compared with non-overweight. Having T2DM was associated with worse survival compared with those without T2DM. Further studies are needed to investigate the underlying mechanisms of these associations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552572 | PMC |
| http://dx.doi.org/10.1136/jitc-2024-009769 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: This report provides prevalence estimates of adult obesity and severe obesity during August 2021-August 2023 by age and sex, as well as obesity prevalence by education level. Trends in the prevalence of adult obesity and severe obesity over the previous 10 years are also shown.
Methods: Data from the August 2021-August 2023 National Health and Nutrition Examination Survey (NHANES) were used for prevalence estimates, incorporating examination survey sample weights into the analysis and accounting for the survey's complex, multistage probability design.
Episiotomies and obstetric anal sphincter injuries following a restrictive episiotomy policy in France: An analysis of the 2010, 2016, and 2021 National Perinatal Surveys.
PLoS Med
January 2025
Université Paris Cité, Center of Research in Epidemiology and StatisticS/CRESS/Obstetrical Perinatal and Pediatric Epidemiology Research Team (EPOPé), INSERM, INRAE, Paris, France.
Background: The French guidelines have recommended a restrictive policy of episiotomy since 2005. We aimed to assess variations in the prevalence of both episiotomy and obstetric anal sphincter injury (OASI) from the 2010, 2016, and 2021 National Perinatal Surveys.
Methods And Findings: A total of 29,750 women who had given birth to a live infant by vaginal delivery were included.
TeMac™ ameliorates memory impairment and cholinergic dysfunction in rats induced by scopolamine.
Metab Brain Dis
January 2025
Department of Biochemistry, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaounde, Cameroon.
Alzheimer's disease (AD) is associated with cognitive impairments which are linked to a deficit in cholinergic function. The objective of this study was to evaluate the ability of TeMac™ to prevent memory impairment in scopolamine-rats model of Alzheimer's disease and by in silico approaches to identify molecules in TeMac™ inhibiting acetylcholinesterase. The cholinergic cognitive dysfunction was induced by intraperitoneal injection of scopolamine (1 mg/kg daily) in male Wistar rats for seven consecutive days.
View Article and Find Full Text PDFObesity and metabolic syndrome in a diverse pediatric kidney transplant population: which anthropometric measure best predicts arterial stiffness?
Pediatr Nephrol
January 2025
Nephrology, Children's National Hospital, 111 Michigan Avenue NW, Washington, DC, 20010, USA.
Background: Obesity and metabolic syndrome (MS) accelerate arterial stiffening, increasing cardiovascular (CV) risk after transplant. BMI is limited by inability to differentiate muscle, fat mass, and fat distribution patterns. The aim of this study was to identify the best anthropometric measure to detect arterial stiffness as assessed by pulse wave velocity (PWV) in a racially diverse pediatric transplant population.
View Article and Find Full Text PDFCluster analysis of sarcopenia in older adults: significant factors contributing to disease severity.
Eur Geriatr Med
January 2025
Federal State Autonomous Educational Institution of Higher Education "Russian National Research Medical University named after N.I. Pirogov" of the Ministry of Health of the Russian Federation, Separate structural unit "Russian Gerontology Research and Clinical Centre", 16 1st Leonova Street, Moscow, Russia, 129226.
Introduction: The European Working Group on Sarcopenia in Older People (EWGSOP2) defines sarcopenia as a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age. New findings on the hormonal and metabolic characteristics of patients with sarcopenia have aided in developing more targeted therapeutic strategies. However, treating older patients with sarcopenia still poses a number of challenges.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!